---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-003924"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:16:36.111290+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vistagen reports narrower net loss of $6.3M in fiscal Q3; fasedienol trials on track

## Summary
- Net loss $6.3M vs $9.8M YoY; cash $126.6M at Dec 31, 2023.
- R&D expense $4.5M, down from $6.9M on lower clinical costs.
- G&A expense $3.8M, up from $3.1M on compensation.
- PALISADE-3 fasedienol trial for SAD initiation expected 1H 2024; PALISADE-4 in 2H 2024.
- Preparations underway for itruvone Phase 2B in MDD and PH80 Phase 2B in vasomotor symptoms.

## SEC filing metadata
- accession: 0001437749-24-003924
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774924003924/0001437749-24-003924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774924003924/vtgn20240213_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-003924
- JSON: https://secwatch.observer/filing/0001437749-24-003924.json
- Plain text: https://secwatch.observer/filing/0001437749-24-003924.txt

## Key facts
- Earnings Releases
  Vistagen Therapeutics, Inc. reported fiscal year 2024 third quarter ended December 31, 2023 results: net income $6.3 million.
  - Period: fiscal year 2024 third quarter ended December 31, 2023
  - Net income: $6.3 million
  - Result: reported results
  source text: Net loss: Net loss was $6.3 million and $9.8 million for the three months ended December 31, 2023, and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774924003924/0001437749-24-003924-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.